Further evidence for a male-selective genetic association of synapse-associated protein 97 (SAP97) gene with schizophrenia

Akihito Uezato1,2,3†, Junko Kimura-Sato1†, Naoki Yamamoto1, Yoshimi Iijima4, Hiroshi Kunugi4 and Toru Nishikawa1*

Abstract
Background: The synapse-associated protein 97 gene (SAP97) encodes a regulatory scaffold protein for the localization of L-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) type glutamate receptors. We have recently demonstrated nominally significant associations between SAP97 gene and schizophrenia among Japanese males. The present study aimed to replicate these findings using an independent and larger sample.

Methods: We investigated seven SAP97 single nucleotide polymorphisms (SNPs) that displayed a significant association with schizophrenia in our preceding study in an independent Japanese population consisting of a total of 393 unrelated patients with schizophrenia (232 males and 161 females) and 393 unrelated control subjects (211 males and 182 females).

Results: The SNP rs9843659 showed a significant genotypic association with male patients in a recessive model (p = 0.037). The analysis of the combined data from the current and prior studies also demonstrated a significant association of this SNP (p = 0.0039). The meta-analysis for the allele frequency covering the two studies yielded an odds ratio of 1.38.

Conclusions: The present study replicated the previously reported male-selective genetic association between the SAP97 polymorphism and schizophrenia. These findings further support the possible involvement of the SAP97 gene variation in the susceptibility to schizophrenia in males and in the genetic basis for sex differences in the disorder.

Keywords: Schizophrenia, genetic association, single nucleotide polymorphisms, synapse-associated protein, scaffolding protein, SAP97, gender selective, glutamate
associated protein 97 gene (SAP97), which encodes a regulatory scaffold protein for the localization of L-alphamino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate and NMDA type glutamate receptors [13], is upregulated in the adult but not in the infant rat after PCP administration [14]. Moreover, we have demonstrated nominally significant associations between SAP97 single nucleotide polymorphisms (SNPs) and schizophrenia among males [15]. In the present study, we therefore aimed to replicate the prior genetic association findings using an independent and larger sample.

Methods
A total of 393 unrelated Japanese patients with schizophrenia (232 males, 41.9 ± 11.4 years, and 161 females, 40.7 ± 12.3 years) and 393 unrelated Japanese control subjects (211 males, 38.6 ± 10.9 years, and 182 females, 41.5 ± 12.9 years) were included in this study. All patients were diagnosed by well-trained psychiatrists, according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria. All patients had prior medical histories of a central nervous system disease or severe head injury, or if they met the criteria for substance abuse or dependence, or mental retardation. This study was conducted in accordance with the latest version of the Declaration of Helsinki.

We selected seven SNPs which displayed a significant association with schizophrenia in the previous study [15]. TaqMan SNP Genotyping Assay method (Applied Biosystems, Foster City, CA, USA) was used to genotype these SNPs as previously described [15]. The representative genotyping results were confirmed by the direct sequence and TA cloning methods.

A statistical analysis was performed using the PLINK 1.07 software package http://pngu.mgh.harvard.edu/purcell/plink/[18]. Deviation from the predicted Hardy-Weinberg equilibrium (HWE) was evaluated by the chi-square test. To compare the allele and genotype frequencies between cases and controls, Fisher’s exact test was performed. The analysis for genotype frequencies was performed assuming dominant, recessive and co-dominant effects for each polymorphism. In the dominant model, both the major allele homozygote and the heterozygote were combined. In the recessive model, the variant was defined as only the major allele homozygote. The co-dominant model compared the major allele homozygote and heterozygote to the minor allele homozygote. A meta-analysis was performed using the package (rmeta) for R-software http://www.r-project.org. When there is no heterogeneity, the fixed-effects (Mantel-Haenszel) model was applied. Otherwise, the random-effects (DerSimonian-Laird) model was used.

Results
The allele frequency and genotype distribution of each SNP are summarized in Table 1. The genotype distribution of all the SNPs showed no significant deviations from the HWE in the control or disease groups (p > 0.05).

Regarding male patients with schizophrenia, we observed a genotypic association between schizophrenia and SNP I-3 (rs9843659) in the recessive model (p = 0.037). Because there was a significant difference in the mean age between patients and controls in the male group (p = 0.0016), we performed a logistic regression analysis in the recessive model to control the possible confounding effect of age. The analysis yielded a statistical significance (p = 0.028). The SNP I-3 association in the recessive model was also demonstrated in the combined data from the current and prior studies (p = 0.0039) (Table 2). The p value remained statistically significant after permutation testing (p = 0.0124, 10,000 permutations). SNP I-3 also showed an association in the co-dominant model as well as an allelic association (Table 2). The combined data further revealed allelic and genotypic associations in SNP II-1 and II-8 (Table 2). The meta-analysis for the allele frequency covering the current and prior studies yielded an odds ratio of 1.38 for SNP I-3, and 1.26 and 1.25 for SNP II-1 and II-8, respectively, in the fixed-effects model (Table 2).

In the present study no significant case-control allele or genotype differences was demonstrated when female patients with schizophrenia were compared to control females or when all subjects were analyzed (Table 1). However, for the combined data from the current and prior studies, we detected significant differences in the allele and genotype frequencies in the recessive and co-dominant models between all patients and controls for SNP I-3, I-10, II-1 and II-8. Likewise, the meta-analyses for the allele frequencies demonstrated statistically significant odds ratios for these SNPs (Table 2).

Discussion
These findings add further support to our previous report in that the SNP rs9843659 in the SAP97 gene is genetically associated with male patients with...
Table 1 Allele frequencies and genotype distribution of SNPs on the SAP97 gene

| SNP | Allele (1/2) | Sex | Group | HWE | 1/1 | 1/2 | 2/2 | Hom | Rec | Codom | Allele Frequency (%) | p value |
|-----|-------------|-----|-------|-----|-----|-----|-----|-----|-----|------|---------------------|---------|
| I-2 Alpha |     |     |       |     |     |     |     |     |     |      |                     |         |
| rs382579 | T/C | M   | CTL  |     |     |     |     |     |     |      | 130 (61.6)         | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 136 (58.6)         | 0.776   |
|         |     | F   | CTL  |     |     |     |     |     |     |      | 116 (63.7)         | 0.776   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 104 (64.6)         | 0.776   |
|         |     |     | All  |     |     |     |     |     |     |      | 246 (62.6)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 130 (33.1)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 116 (59.5)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 104 (62.3)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 246 (62.6)         | 0.776   |
| I-3 Alpha |     |     |       |     |     |     |     |     |     |      |                       |         |
| rs9843659 | T/C | M   | CTL  |     |     |     |     |     |     |      | 86 (40.8)          | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     | F   | CTL  |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
|         |     |     | All  |     |     |     |     |     |     |      | 156 (59.7)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 86 (40.3)          | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
| I-4 Alpha |     |     |       |     |     |     |     |     |     |      |                       |         |
| rs2122824 | G/T | M   | CTL  |     |     |     |     |     |     |      | 126 (59.7)         | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     | F   | CTL  |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
|         |     |     | All  |     |     |     |     |     |     |      | 239 (60.8)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 126 (59.7)         | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
| I-5 Alpha |     |     |       |     |     |     |     |     |     |      |                       |         |
| rs7650753 | G/T | M   | CTL  |     |     |     |     |     |     |      | 126 (59.7)         | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     | F   | CTL  |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
|         |     |     | All  |     |     |     |     |     |     |      | 238 (60.8)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 126 (59.7)         | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 131 (56.5)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 113 (62.1)         | 0.776   |
|         |     |     |       |     |     |     |     |     |     |      | 100 (62.1)         | 0.776   |
| I-10 Alpha |    |     |       |     |     |     |     |     |     |      |                       |         |
| rs7638423 | A/G | M   | CTL  |     |     |     |     |     |     |      | 98 (46.4)          | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 98 (46.4)          | 0.561   |
|         |     | F   | CTL  |     |     |     |     |     |     |      | 88 (41.7)          | 0.561   |
|         |     |     | SCZ  |     |     |     |     |     |     |      | 84 (46.2)          | 0.561   |
|         |     |     | All  |     |     |     |     |     |     |      | 186 (46.8)         | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 98 (46.4)          | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 88 (41.7)          | 0.561   |
|         |     |     |       |     |     |     |     |     |     |      | 84 (46.2)          | 0.561   |

**SNP**: single-nucleotide polymorphism; **HWE**: Hardy-Weinberg equilibrium; **M**: male; **F**: female; **All**: male and female combined; **CTL**: control; **SCZ**: schizophrenia; **Dom**: dominant model; **Rec**: recessive model; **Codom**: co-dominant model.

Bold values indicate significance level p < 0.05.

*Allele 1 and 2 represent the major and minor alleles of each SNP.*
The allele C of this SNP conferred a risk for schizophrenia susceptibility. The allele C of this SNP conferred a risk for schizophrenia susceptibility in both studies. As replicating results of a genetic association study in independent samples is considered as a standard to demonstrate the relevance of a candidate gene [19], the results of the present study in conjunction with the previous study strongly support the view that SAP97 is a risk gene for male patients with schizophrenia.

In the most recent and largest genome-wide association studies (GWAS), the tag SNP rs192705 on chromosome 3q29 closest to the SNP rs9843659 in the SAP97 gene demonstrated a nominal genome-wide significance \((p = 8.45 \times 10^{-8})\) [20-22]. Another genome-wide analysis of the copy-number variation (CNV) found a statistically significant excess of deletions in schizophrenia at 3q29 [23]. The telomeric breakpoint of the minimal deletion in this study was 4.7 kb from the transcriptional stop of the SAP97 gene. These findings also implicate SAP97 as a candidate gene for schizophrenia susceptibility.

The contributions of the rs9843659 polymorphism to the development of schizophrenia remains unexplained because 1) this SNP is found in the fourth large intron, but not in the exons that encode the amino acid sequences of the SAP97 protein including the functional domains and motifs, and 2) as previously described, bioinformatics tools we used failed to reveal any consensus sequences in the intron part that may play a role in the alternative promoter use or alternative splicing. The rs9843659 polymorphism could cause certain modifications in the regulation of transcription or translation of the SAP97 gene by an unidentified mechanism, for instance, a change in its higher-order genome structure. This type of a ‘silent’ SNP has indeed been observed to alternate substrate specificity in the Multidrug Resistance 1 (MDRI) gene [24].

From this viewpoint, it is of interest to note that the expression changes of the SAP97 proteins have been reported by two independent research groups in the dorsolateral prefrontal cortex of postmortem schizophrenic brains [25,26]. However, it is not totally excluded that these results might be due to long-term treatment with antipsychotic drugs [25,26] and another research group failed to observe any significant alteration in the SAP97 mRNA level in the cortical area [27]. Furthermore, animal experiments have revealed the mutual interactions between SAP97 and the NMDA receptor that is hypothesized to be dysfunctional in schizophrenia brains. Thus, the SAP97 gene knockdown reduced the surface expression of GluR1 and GluR2 and inhibited both the AMPA and NMDA excitatory postsynaptic currents (EPSCs) [28], and the NMDA antagonists upregulated the SAP97 mRNA expression in the cerebral cortex [14]. A more recent in vitro study using transfection, viral infection, small interference RNA, and antisense oligonucleotide techniques has demonstrated in the rat prefrontal cortex a functional link of the SAP97 proteins with the D4 type dopamine receptor that is possibly aberrant in mental illnesses including schizophrenia [29]. Taken together, the presumed dysregulation of the SAP97 gene connected to the rs9843659 polymorphism could lead to the plausible NMDA receptor deficits and/or abnormal dopamine neurotransmission in patients with schizophrenia.

The replicated male-selective genetic association of SAP97 gene with schizophrenia appears to be in line with the data indicating the sex-specific genetic associations with the disorder reported in several genes such as

### Table 2 Combined analysis and meta-analysis from the current and prior studies

| SNP | Allelic | Combined analysis (p value) | Meta-analysis<sup>a</sup> |
|-----|---------|-----------------------------|---------------------------|
|     | Allelic | Dom Rec Codom Odds Ratio (95% CI) |
|     | All    | M F All | M F All |
| SNP I-2 rs382579 | M | 0.179 0.409 0.214 0.404 | 1.19 (0.92-1.53) |
|     | F | 0.494 1.000 0.475 0.751 | 1.11 (0.82-1.50) |
|     | All | 0.107 0.418 0.115 0.260 | 1.17 (0.97-1.42) |
| SNP I-3 rs9843659 | M | 0.004 0.121 0.004 0.011 | 1.38 (1.11-1.71) |
|     | F | 0.757 1.000 0.594 0.835 | 1.04 (0.82-1.33) |
|     | All | 0.014 0.210 0.011 0.034 | 1.22 (1.04-1.44) |
| SNP I-4 rs2122824 | M | 0.089 0.409 0.105 0.222 | 1.24 (0.96-1.59) |
|     | F | 0.657 0.527 0.427 0.436 | 1.07 (0.80-1.43) |
|     | All | 0.085 0.698 0.064 0.165 | 1.18 (0.98-1.42) |
| SNP I-5 rs7650753 | M | 0.115 0.327 0.164 0.275 | 1.22 (0.95-1.57) |
|     | F | 0.712 0.527 0.480 0.471 | 1.06 (0.79-1.42) |
|     | All | 0.114 0.607 0.104 0.246 | 1.18 (0.98-1.42) |
| SNP I-10 rs7638423 | M | 0.078 0.497 0.053 0.142 | 1.23 (0.98-1.53) |
|     | F | 0.303 0.783 0.100 0.150 | 1.06 (0.79-1.42) |
|     | All | 0.038 0.727 0.010 0.028 | 1.20 (1.01-1.41) |
| SNP II-1 rs6805920 | M | 0.041 0.497 0.020 0.061 | 1.26 (1.01-1.58) |
|     | F | 0.200 1.000 0.068 0.133 | 1.06 (0.79-1.42) |
|     | All | 0.014 0.602 0.003 0.009 | 1.23 (1.04-1.46) |
| SNP II-8 rs4916461 | M | 0.046 0.420 0.037 0.104 | 1.25 (1.00-1.57) |
|     | F | 0.269 0.888 0.120 0.215 | 1.16 (0.90-1.49) |
|     | All | 0.021 0.532 0.008 0.027 | 1.22 (1.03-1.44) |

<sup>a</sup>Combined analysis was performed on the combined data from the current study and Sato et al.<n
<sup>b</sup>Meta-analysis was performed covering the current study and Sato et al. for allele frequency

SNP, single-nucleotide polymorphism; M, male; F, female; All, male and female combined; Dom, dominant model; Rec, Recessive model; Codom, Co-dominant model; CI, confidence interval. Bold values indicate significance level \(p < 0.05\).
Disrupted-In-Schizophrenia 1 (DISC1), reelin (RELN) and D-amino acid oxidase (DAO) [30-32]. These phenomena might be related to the well-known gender differences in schizophrenia [33] that, for instance, include the clinical observations that male patients tend to exhibit an earlier onset and severer course than female patients, although the genetic basis of the sex-differences in schizophrenia remains unclear. Consequently, the male-specific association seen in the SAP97 gene could produce different influences on the putative disturbed neurotransmission via the NMDA receptor between male and female patients with schizophrenia.

Conclusions

In conclusion, the present findings have confirmed that the glutamatergic transmission-linked and developmentally-regulated schizophrenomimetic-responsive gene SAP97 is associated with male patients with schizophrenia. As this unique association could provide a clue to elucidating the pathological changes in the glutamate system and their gender differences, further investigations are required in the larger and non-Japanese populations to extend its validity.

List of abbreviations

SAP97: synapse-associated protein 97; AMPA: L-alpha-aminoo-3-hydroxy-5-methyl-4-isoxazole propionic acid, NMDA: N-methyl-D-aspartate; SNP: single nucleotide polymorphism; PCP: phencyclidine; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; M.I.N.I.: Mini-International Neuropsychiatric Interview; HWE: Hardy-Weinberg equilibrium; GWAS: genome-wide association studies; CNV: copy-number variation; MDR1: Multidrug Resistance 1; EPSCs: excitatory postsynaptic currents; DISC1: Disrupted-In-Schizophrenia 1; DAO: D-amino acid oxidase.

Acknowledgements and funding

This study is supported by the research grant for the “Development of biomarker candidates for social behavior” carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Dr. Takeo Yoshikawa for his helpful advice about the genome analyses.

Author details

1Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. 2Department of Sleep Modulatory Program, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. 3Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, 1530 3rd Ave S, Birmingham, AL 35294, USA. 4Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashimachi, Kodaira, Tokyo 187-8502, Japan.

Authors’ contributions

AU undertook the statistical analysis and wrote the manuscript. JKS carried out the SNP genotyping and collected the data. NY supervised the data collection and analysis. YI and HK organized the recruitment of subjects and prepared them for the blood samples. TN designed and managed the entire procedure of this study. All authors contributed and have approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. McGuffin P, Owen M, Farmer A: Genetic basis of schizophrenia. Lancet 1995, 346:678-682.
2. Allen N, Bagadie S, McQueen M, Ioannidis J, Kayeourea F, Khouy M, Tanzi R, Bertram L: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834.
3. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
4. Nishikawa T, Hashimoto A, Tani Y, Umino A, Kashwa A, Oka T, Nishijima K, Takahashi K: Excitatory amino acidergic dysfunction and schizophrenia. Journal of Neurochemistry 1992, 59:52-52.
5. Reich D, Silvay G: Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989, 36:186-197.
6. White P, Way W, Trevor A: Ketamine—its pharmacology and therapeutic uses. Anesthesiology 1982, 56:119-136.
7. Schwartz R, Einhorn A: PCP intoxication in young seven children. Pediatr Emerg Care 1986, 2:238-241.
8. Welch M, Correa G: PCP intoxication in young children and infants. Clin Pediatr (Philadelphia) 1980, 19:10-15.
9. Buchanan R, Carpenter W: Concept of Schizophrenia. In Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 8 edition. Edited by: Sadock B, Sadock V. New York: Lippincott Williams 2005:1329-1345.
10. Takebayashi H, Yamamoto N, Umino A, Nishikawa T: Developmentally regulated and thalamus-selective induction of leiomodin2 gene by a schizophrenomimetic phenylcyclidine, in the rat. Int J Neuropsychopharmacol 2009, 1:16.
11. Sato D, Umino A, Kaneda K, Takigawa M, Nishikawa T: Developmental changes in distribution patterns of phencyclidine-induced c-Fos in rat forebrain. Neurosci Lett 1997, 239:21-24.
12. Scalzo F, Burgie L: The role of NMDA and sigma systems in the behavioral effects of phencyclidine in preweaning rats. Neurotoxicology 1994, 15:191-200.
13. Howard M, Elias G, Elias L, Swat W, Nicoll R: The role of SAP97 in synaptic glutamate receptor dynamics. Proc Natl Acad Sci USA 2010, 107:3805-3810.
14. Hiroaka S, Kaji Y, Kuroda Y, Umino A, Nishikawa T: The development- and phencyclidine-regulated induction of synapse-associated protein-97 gene in the rat neocortex. Eur Neuropsychopharmacol 2010, 20:176-186.
15. Sato J, Shinmazu D, Yamamoto N, Nishikawa T: An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia. J Neural Transm 2008, 115:1355-1365.
16. Otsubo T, Miyakova H, Kamijima K: MINI. Mini international neuropsychiatric interview. Tokyo: Seiwa Shoten Publishers; 2005.
17. Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured neuropsychiatric interview. J Clin Psychiatry 1998, 59(Suppl 20):22-33, quiz 34-57.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
19. Ioannidis J, Ntzani E, Trikalinos T, Contopoulos-Ioannidis D: Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.
20. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Peter I, Dudbridge F, Holmans PA, Whitemore AS, Howy B, et al: Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
21. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, et al: Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
22. Purcell SM, Wher MAP, Stone J, Visscher PM, O’Donovan MC, Sullivan PK, Sklar P: Consortium IS: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
23. Molle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobrera NL, Valle D, Rudd MK, Satten G, et al: Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet 2010, 87:229-236.
24. Kimchi-Sarfaty C, Oh J, Kim I, Sauna Z, Calcagno A, Ambudkar S, Gottesman M: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.

25. Hammond J, McCullumsmith R, Funk A, Haroutunian V, Meador-Woodruff J: Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 2010, 35:2110-2119.

26. Toyooka K, Iritani S, Makifuchi T, Shirakawa O, Kitamura N, Maeda K, Nakamura R, Nizato K, Watanabe M, Kakita A, et al: Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 2002, 83:797-806.

27. Dracheva S, McGurk S, Haroutunian V: mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res 2005, 79:868-878.

28. Nakagawa T, Futai K, Lashuel H, Lo I, Okamoto K, Walz T, Hayashi Y, Sheng M: Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions. Neuron 2004, 44:453-467.

29. Yuen EY, Yan Z: Cellular mechanisms for dopamine D4 receptor-induced homeostatic regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J Biol Chem 2011, 286:24957-24965.

30. Hennah W, Varilo T, Kestilä M, Paunio T, Arajärvi R, Haukka J, Parker A, Martin R, Levitidz S, Partonen T, et al: Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Genet 2003, 12:3151-3159.

31. Shifman S, Johannisson M, Bronstein M, Chen S, Collier D, Craddock N, Kendler K, Li T, O’Donovan M, O’Neill F, et al: Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet 2008, 4:e628.

32. Kim B, Kim H, Joo Y, Lim J, Kim C, Song K: Sex-different association of DAO with schizophrenia in Koreans. Psychiatry Res 2010, 179:121-125.

33. Leung A, Chue P: Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000, 101:3-38.

Cite this article as: Uezato et al.: Further evidence for a male-selective genetic association of synapse-associated protein 97 (SAP97) gene with schizophrenia. Behavioral and Brain Functions 2012 8:2.